Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of
one ligand that binds to a protein of interest (POI) and another that can recruit an E3 …

In recent years, proteolysis-targeting chimeras (PROTACs), capable of achieving targeted
protein degradation, have proven their great therapeutic potential and usefulness as …

Targeted protein degradation induced by heterobifunctional compounds and molecular
glues presents an exciting avenue for chemical probe and drug discovery. To date, small …

Immunotherapy is recognised as an attractive method for the treatment of cancer, and
numerous treatment strategies have emerged over recent years. Investigations of the tumour …

Proteolysis-targeting chimeras (PROTACs) as an emerging drug discovery modality has
been extensively concerned in recent years. Over 20 years development, accumulated …

The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …

Targeted protein degradation (TPD) is an emerging technique for protein regulation.
Currently, all TPD developed in eukaryotic cells relies on either ubiquitin-proteasome or …

A challenge in developing proteolysis targeting chimeras (PROTACs) is the establishment of
a universal platform applicable in multiple scenarios for precise degradation of proteins of …

Reader domains that recognize methylated lysine and arginine residues on histones play a
role in the recruitment, stabilization, and regulation of chromatin regulatory proteins …

Covalent antibody recruiting molecules (cARMs) constitute a proximity-inducing chemical
strategy to modulate the recognition and elimination of cancer cells by the immune system …